BY STAFF REPORTER
The U.S. Embassy in Zimbabwe has announced an exciting development in the fight against HIV: Zimbabwe has been selected as one of the ten countries globally to roll out lenacapavir, a breakthrough in HIV prevention.
“Yes Zimbabwe, it’s happening!” the embassy declared, highlighting the significance of this initiative.
“For decades, we’ve fought to turn the tide against this epidemic, and each day we get closer,” the statement continued. This new treatment represents a pivotal moment in HIV prevention efforts, as it is the first twice-yearly HIV prevention medicine.
The implementation of lenacapavir is made possible through a partnership with U.S.-based Gilead Sciences and the Global Fund. A key finding from a large-scale clinical trial shows that more than 99% of people on lenacapavir remained HIV negative. While this has the potential to save millions of lives, the Embassy emphasized that for Zimbabwe, it represents a major step toward ending new infections.
“But this is more than medicine—it advances us on a pathway to a safer, stronger, and healthier future!” noted the embassy’s announcement.
The initiative particularly focuses on pregnant and breastfeeding women, aiming to protect the next generation. It will also work toward strengthening healthcare systems, empowering Zimbabwe to lead its own fight against HIV. Moreover, the goal of making lenacapavir more affordable and accessible ensures that no one is left behind.
The embassy highlighted, “This is American leadership at its best: driving innovation, and building a world where children, mothers, and communities can thrive.”
As this initiative rolls out, the message is clear: “Together, we’re not just fighting HIV—we’re winning.”